Senti Biosciences (NASDAQ:SNTI) Upgraded at Wall Street Zen

Senti Biosciences (NASDAQ:SNTI) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities research analysts have also recently weighed in on SNTI. Chardan Capital increased their price objective on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Senti Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Senti Biosciences Trading Down 10.4%

Shares of NASDAQ:SNTI opened at $0.79 on Friday. The company has a 50-day moving average price of $0.95 and a 200-day moving average price of $1.38. The company has a market cap of $20.77 million, a price-to-earnings ratio of -0.24 and a beta of 2.12. Senti Biosciences has a 12 month low of $0.79 and a 12 month high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last posted its earnings results on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $1.00 million. As a group, research analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Senti Biosciences

A number of institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new stake in Senti Biosciences in the second quarter worth about $1,883,000. Geode Capital Management LLC boosted its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences during the 3rd quarter worth approximately $117,000. Virtu Financial LLC purchased a new position in shares of Senti Biosciences during the 4th quarter worth approximately $46,000. Finally, Jane Street Group LLC bought a new position in shares of Senti Biosciences in the 4th quarter worth approximately $40,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.